Traws Pharma's ratutrelvir shows fewer treatment-related adverse events than Paxlovid in Phase 2a trial
TRAW•Traws Pharma reported final Phase 2a results showing ratutrelvir had symptom resolution comparable to Paxlovid, with fewer treatment-related adverse events and no viral rebound through follow-up. The company also reported progress on tivoxavir marboxil and plans an FDA regulatory resubmission in the fourth quarter of 2026.
1. Phase 2a results
Traws Pharma said final Phase 2a results showed ratutrelvir delivered symptom resolution comparable to Paxlovid, with fewer treatment-related adverse events and no viral rebound through follow-up. Paxlovid-ineligible patients receiving ratutrelvir had similar outcomes without treatment-related adverse events. The company plans FDA discussions about a registration pathway for high-risk adults ineligible for Paxlovid.
2. Other development updates
Traws Pharma said a completed tablet bridging study for tivoxavir marboxil supported potential once-monthly influenza prevention dosing, and the formulation was well tolerated. Completed toxicology retesting supports a planned regulatory resubmission in the fourth quarter of 2026.
